{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:49:31Z","timestamp":1762642171956},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11899-019-0498-6","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T09:03:21Z","timestamp":1548061401000},"page":"47-55","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Industry\u2019s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy"],"prefix":"10.1007","volume":"14","author":[{"given":"Stacie","family":"Ittershagen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solveig","family":"Ericson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamis","family":"Eldjerou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Shojaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bleickardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"Taran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oezlem","family":"Anak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Roccoberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Romanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"498_CR1","unstructured":"Kymriah (tisagenlecleucel) suspension for intravenous infusion [package insert]. East Hanover, NJ: Novartis Pharmceuticals Corporation; 2018."},{"issue":"8","key":"498_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1103849\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"95","key":"498_CR3","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.3002842\n                      \n                    .","journal-title":"Sci Transl Med"},{"key":"498_CR4","unstructured":"June CH. Chimeric antigen receptors: engineering designer T cells for cancer therapy. Presented at: 2012 American Society of Clinical Oncology annual meeting, June 5, 2012; Chicago, IL. Available at: \n                      https:\/\/meetinglibrary.asco.org\/record\/68679\/video\n                      \n                    . Accessed November 7, 2018."},{"key":"498_CR5","unstructured":"Penn Medicine. University of Pennsylvania and Novartis form Alliance to expand use of personalized T cell therapy for Cancer patients [press release]. Available at: \n                      https:\/\/www.pennmedicine.org\/news\/news-releases\/2012\/august\/university-of-pennsylvania-and\n                      \n                    . Accessed November 7, 2018. Philadelphia, PA: Penn Medicine; 2012."},{"key":"498_CR6","unstructured":"Penn Medicine. Novartis-Penn Center for advanced cellular therapeutics unveiled at Penn medicine [press release]. Available at: \n                      https:\/\/www.pennmedicine.org\/news\/news-releases\/2016\/february\/novartispenn-center-for-advanc\n                      \n                    . Accessed November 7, 2018. Philadelphia, PA: Penn Medicine; 2016."},{"key":"498_CR7","unstructured":"United States Adopted Names Council. Tisagenleceleucel (BC-84). Statement on a nonproprietary name adopted by the USAN council. March 29, 2017. Available at: \n                      https:\/\/searchusan.ama-assn.org\/undefined\/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Ftisagenlecleucel.pdf\n                      \n                    . Accessed November 7, 2018."},{"key":"498_CR8","unstructured":"Lebwohl D. KYMRIAH (tisagenlecleucel) case study: CD-19-directed genetically modified autologous T-cell immunotherapy for pediatric acute lymphoblastic leukemia (ALL). Presented at: Accelerating Anticancer Agent Development Validation Workshop; May 2-4, 2018."},{"key":"498_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101. \n                      https:\/\/doi.org\/10.1016\/j.omtm.2016.12.006\n                      \n                    .","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"20","key":"498_CR10","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","volume":"17","author":"V Blanc","year":"2011","unstructured":"Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448\u201358. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0485\n                      \n                    .","journal-title":"Clin Cancer Res"},{"key":"498_CR11","unstructured":"Clinicaltrials.gov. Pilot study of redirected autologous T-cells engineered to contain anti-CD19 attached to TCR and 4-1BB signaling domains in patient with chemotherapy resistant or refractory CD19+ leukemia and lymphoma. NCT01029366. Available at: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01029366\n                      \n                    . Accessed November 7, 2018."},{"key":"498_CR12","unstructured":"Clinicaltrials.gov. Pilot study of donor lymphocyte infusions using donor T cells engineered to contain anti-CD19 attached to TCR And 4-1BB signaling domains in patients with relapsed CD19+ ALL after allogeneic stem cell transplantation. NCT01551043. Available at: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01551043\n                      \n                    . Accessed November 7, 2018."},{"key":"498_CR13","unstructured":"Clinicaltrials.gov. CHP 959 - A phase I\/IIA study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRzeta and 4-1BB signaling domains in patients with chemotherapy resistant or refractory CD19+ leukemia and lymphoma. NCT01626495. Available at: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01626495\n                      \n                    . Accessed November 7, 2018."},{"issue":"16","key":"498_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1407222\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"498_CR15","unstructured":"Clinicaltrials.gov. A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia. NCT02228096. Available at: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02228096\n                      \n                    . Accessed November 7, 2018."},{"key":"498_CR16","unstructured":"Clinicaltrials.gov. A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia. NCT02435849. Available at: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02435849\n                      \n                    . Accessed November 7, 2018."},{"issue":"26","key":"498_CR17","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1708566\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"498_CR18","unstructured":"Clinicaltrials.gov. A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NCT02445248. Available at: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02445248\n                      \n                    . Accessed November 7, 2018."},{"issue":"5","key":"498_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"\u2022\u2022 Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1709866\n                      \n                    \n                              Publication of the ELIANA clinical trial, which led to regulatory approval of tisagenlecleucel for pediatric and young adult patients with acute lymphoblastic leukemia.","journal-title":"N Engl J Med"},{"key":"498_CR20","unstructured":"\u2022\u2022 Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018 [in press]. Publication of the JULIET clinical trial, which led to regulatory approval of tisagenlecleucel for adult patients with diffuse large B-cell lymphoma."},{"issue":"16","key":"498_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1215134\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"4","key":"498_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724\u201340. \n                      https:\/\/doi.org\/10.1016\/j.cell.2017.01.016\n                      \n                    .","journal-title":"Cell"},{"key":"498_CR23","unstructured":"Novartis Pharmaceuticals Corporation. Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r\/r B-cell ALL [press release]. Available at: \n                      https:\/\/www.novartis.com\/news\/media-releases\/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-approval-fda\n                      \n                    . Accessed November 7, 2018. East Hanover, NJ: Novartis Pharmaceuticals Corporation."},{"issue":"15","key":"498_CR24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMp1807382","volume":"379","author":"PB Bach","year":"2018","unstructured":"Bach PB. National coverage analysis of CAR-T therapies - policy, evidence, and payment. N Engl J Med. 2018;379(15):1396\u20138. \n                      https:\/\/doi.org\/10.1056\/NEJMp1807382\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"498_CR25","unstructured":"Hao Y, Eldjerou L, Yang H, Qi CZ, Globe D. Cost-effectiveness analysis of Kymriah\u2122 for the treatment of pediatric and young adult patients with relapsed or refractory B-Cell acute lymphoblastic leukemia in the United States. Presented at: American Society of Hematology Annual Meeting; December 9\u201312, 2017; Atlanta, GA. Abstract 609."},{"issue":"1","key":"498_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141. \n                      https:\/\/doi.org\/10.1186\/s13045-018-0681-6\n                      \n                    .","journal-title":"J Hematol Oncol"},{"issue":"1","key":"498_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138. \n                      https:\/\/doi.org\/10.1038\/nm.4441\n                      \n                    .","journal-title":"Nat Med"},{"key":"498_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics. 2018;11:127\u201337. \n                      https:\/\/doi.org\/10.1016\/j.omto.2018.10.006\n                      \n                    .","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"498_CR29","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41598-018-22252-6","volume":"8","author":"JH Cho","year":"2018","unstructured":"Cho JH, Okuma A, Al-Rubaye D, Intisar E, Junghans RP, Wong WW. Engineering Axl specific CAR and SynNotch receptor for cancer therapy. Sci Rep. 2018;8(1):3846. \n                      https:\/\/doi.org\/10.1038\/s41598-018-22252-6\n                      \n                    .","journal-title":"Sci Rep"},{"issue":"9","key":"498_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183\u201397. \n                      https:\/\/doi.org\/10.15252\/emmm.201607485\n                      \n                    .","journal-title":"EMBO Mol Med"},{"issue":"5_suppl","key":"498_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2018.36.5_suppl.12","volume":"36","author":"OO Yeku","year":"2018","unstructured":"Yeku OO, Purdon T, Spriggs DR, Brentjens RJ. Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer. J Clin Oncol. 2018;36(5_suppl):12. \n                      https:\/\/doi.org\/10.1200\/JCO.2018.36.5_suppl.12\n                      \n                    .","journal-title":"J Clin Oncol"},{"key":"498_CR32","unstructured":"Majors BS, Spencer T, Ericson SG, Romanov V. Initial experience in US commercial manufacturing of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell therapy for pediatric relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Presented at: 23rd European Hematology Association Meeting; June 14\u201317, 2018; Stockholm, Sweden. Abstract PS1156."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-0498-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-0498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-0498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:11:59Z","timestamp":1579565519000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-0498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-0498-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"21 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Stacie Ittershagen, Lamis Eldjerou, Eric Bleickardt, Manisha Patel, Oezlem Anak, Charlene Hall, Mimi Leung, Ali Shojaee, Deborah Roccoberton, Miriam Fuchs, and Florence Salmon declare that they are employees of Novartis Pharmaceuticals Corporation.Solveig Ericson, Tetiana Taran, Vadim Romanov, and David Lebwohl declare that they are employees and shareholders of Novartis Pharmaceuticals Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:\/\/ExternalRef removed\/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open Access"}}]}}